(1) Tokumasu M (2) Nishida M (3) Zhao W (4) Chao R (5) Imano N (6) Yamashita N (7) Hida K (8) Naito H (9) Udono H
Tokumasu and Nishida et al. demonstrated that metformin combined with anti-PD-1 therapy enhanced CD8+ T cell infiltration and IFNγ production, leading to tumor blood vessel normalization and improved pericyte coverage. The combination therapy induced high endothelial venule-like structure, VE-cadherin, and VCAM-1 expression on endothelial cells, and reduced vascular leakage. Treatment with anti-CD8 or anti-IFNγ antibodies abolished the vessel normalization during combination therapy, highlighting their critical roles. Higher levels of VE-cadherin correlated with improved patient survival on ICB therapy.
Contributed by Shishir Pant
(1) Tokumasu M (2) Nishida M (3) Zhao W (4) Chao R (5) Imano N (6) Yamashita N (7) Hida K (8) Naito H (9) Udono H
Tokumasu and Nishida et al. demonstrated that metformin combined with anti-PD-1 therapy enhanced CD8+ T cell infiltration and IFNγ production, leading to tumor blood vessel normalization and improved pericyte coverage. The combination therapy induced high endothelial venule-like structure, VE-cadherin, and VCAM-1 expression on endothelial cells, and reduced vascular leakage. Treatment with anti-CD8 or anti-IFNγ antibodies abolished the vessel normalization during combination therapy, highlighting their critical roles. Higher levels of VE-cadherin correlated with improved patient survival on ICB therapy.
Contributed by Shishir Pant
ABSTRACT: Tumor blood vessels are highly leaky in structure and have poor blood perfusion, which hampers infiltration and function of CD8T cells within tumor. Normalizing tumor vessels is thus thought to be important in promoting the flux of immune T cells and enhancing ant-tumor immunity. However, how tumor vasculature is normalized is poorly understood. Metformin (Met) combined with ant-PD-1 therapy is known to stimulate proliferation of and to produce large amounts of IFNγ from tumor-infiltrating CD8T lymphocytes (CD8TILs). We found that the combination therapy promotes the pericyte coverage of tumor vascular endothelial cells (ECs) to improve blood perfusion and that it suppresses the hyperpermeability through the increase of VE-cadherin. Peripheral node addressin(PNAd) and vascular cell adhesion molecule (VCAM)-1, both implicated to promote tumor infiltration of CD8T cells, were also increased. Importantly, tumor vessel normalization, characterized as the reduced 70-kDa dextran leakage and the enhancement of VE-cadherin and VCAM-1, were canceled by anti-CD8 Ab or anti-IFNγ Ab injection to mice. The increased CD8TILs were also abrogated by anti-IFNγ Ab injection. In vascular ECs, flow cytometry analysis revealed that pSTAT1 expression was found to be associated with VE-cadherin expression. Moreover, in vitro treatment with Met and IFNγ enhanced VE-cadherin and VCAM-1 on human umbilical vein endothelial cells (HUVECs). The Kaplan-Meier method revealed a correlation of VE-cadherin or VCAM-1 levels with overall survival in patients treated with immune checkpoint inhibitors. These data indicate that IFNγ-mediated cross talk of CD8TILs with tumor vessels is important for creating a better tumor microenvironment and maintaining sustained antitumor immunity.
Author Info: (1) Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. (2) Department of Immunology, Okayama
Author Info: (1) Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. (2) Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. (3) Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. (4) Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. (5) Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. (6) Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. (7) Vascular Biology and Molecular Pathology, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo 060-8586, Japan. (8) Department of Vascular Physiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8640, Ishikawa, Japan. (9) Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
Citation: Proc Natl Acad Sci U S A 2024 Jul 23 121:e2404778121 Epub07/17/2024